Literature DB >> 22759629

Determinants of fibrin formation, structure, and function.

Alisa S Wolberg1.   

Abstract

PURPOSE OF REVIEW: Fibrinogen is the protein substrate of the multifaceted procoagulant and proinflammatory enzyme, thrombin. Fibrin, the product of thrombin's proteolytic cleavage of fibrinogen, provides biophysical and biochemical support to blood clots, and subsequent degradation of fibrin by plasmin is a critical inflammatory mediator and essential step in wound healing. As such, fibrin(ogen) lies at the nexus of vascular injury and repair. Herein, we review aspects of fibrin(ogen) formation, structure, stability, and function, focusing on novel findings within the past 2 years. RECENT
FINDINGS: Early research into specific properties of fibrinogen and fibrin revealed complex kinetics by which fibrinogen is converted to a fibrin network in vitro. These findings laid important groundwork for current in-vivo studies on the role of fibrin(ogen) in hemostasis and thrombosis. Recent studies show novel mechanisms regulating fibrinogen expression, as well as novel roles of fibrinogen in infection, inflammation, and cognitive disorders.
SUMMARY: Expression of fibrinogen and interactions between fibrinogen and other proteins are essential for homeostasis. However, recent findings show abnormal fibrinogen modifications and/or increased fibrin formation and network stability promote thrombosis, as well as disorders not previously associated with coagulation. These findings highlight the increasingly important role of fibrin(ogen) in health and disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22759629     DOI: 10.1097/MOH.0b013e32835673c2

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  18 in total

Review 1.  Mechanisms of fibrin polymerization and clinical implications.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

2.  Structural basis for the nonlinear mechanics of fibrin networks under compression.

Authors:  Oleg V Kim; Rustem I Litvinov; John W Weisel; Mark S Alber
Journal:  Biomaterials       Date:  2014-05-16       Impact factor: 12.479

3.  Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.

Authors:  Paul Y Kim; Trang T Vu; Beverly A Leslie; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

Review 4.  The role of molecular imaging in diagnosis of deep vein thrombosis.

Authors:  Sina Houshmand; Ali Salavati; Søren Hess; Mudalsha Ravina; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

Review 5.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

6.  Hemodynamics-driven deposition of intraluminal thrombus in abdominal aortic aneurysms.

Authors:  P Di Achille; G Tellides; J D Humphrey
Journal:  Int J Numer Method Biomed Eng       Date:  2016-10-07       Impact factor: 2.747

7.  Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin.

Authors:  Trang T Vu; Alan R Stafford; Beverly A Leslie; Paul Y Kim; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

8.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

9.  Loss of fibrinogen in zebrafish results in symptoms consistent with human hypofibrinogenemia.

Authors:  Andy H Vo; Alok Swaroop; Yang Liu; Zachary G Norris; Jordan A Shavit
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

10.  Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice.

Authors:  Reheman Adili; Madeline Jackson; Livia Stanger; Xiangrong Dai; Mandy Li; Benjamin Xiaoyi Li; Michael Holinstat
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.